Mylan: latest news - GoINPHARMA
Monday, 10 December 2018 - 14:12

Mylan

New problems for Mylan and Pfizer’s EpiPens

FDA last Friday announced that Mylan and Pfizer are still experiencing issues in supplying the North American market with EpiPens. The problems involve both EpiPens and its generic version, both developed and marketed by Mylan, but manufactured by its partner…

Stada and Mylan targeting Bristol-Myers Squibb’s Upsa (€1bn)

Germany-based generics producer Stada is reportedly targeting French OTC manufacturer Upsa, owned by Bristol-Myers Squibb. The news has been reported by Reuters, according to which Mylan and France-based Pierre Fabre are targeting the company too. Upsa has 1,500 employees and…

Novartis signed deal with Adamis to gun for Mylan EpiPen’s market

Novartis was granted via subsidiary company Sandoz the U.S. commercial rights for Symjepi, an allergic reaction treatment developed by Adamis Pharmaceuticals. As a matter of fact, Symjepi is a prefilled epinephrine syringe, that is the same active substance as Mylan’s…

First results from GSK’s combo HIV therapy

ViiV, a subsidiary of  GlaxoSmithKline’s having also Pfizer and Shionogi as shareholders, has reported positive early results from the Phase III Gemini-1 and Gemini-2 clinical trials, enrolling 1,400 patients with HIV, treated with a dolutegravir-lamivudine combo therapy for 48 weeks….

Mylan’s biosimilar to Neulasta (Amgen) approved

Mylan’s shares (NASDAQ) today rose by over 3% (+8% intraday) as it was announced that FDA had granted approval to the biosimilar to Amgen’s Neulasta.  Neulasta is a $4.53bn-worth (2017) blockbuster for the treatment of infections in cancer patients. The…

Pfizer lies behind Mylan’s issues with Epipen

Mylan’s EpiPens is hard to be found in Canada and the UK and in severe shortage in the US. The problem is due to Pfizer, acting as a supplier to Mylan, which is experiencing issues in manufacturing enough product units…

Unsatisfactory fourth quarter from Mylan

Mylan yesterday announced its Q4 2017 financial results, which were below analysts’ expectations. Sales were $3.24bn, instead of the expected $3.3bn, net profit reached $244.3m, that is a decline as compared to 2016 ($417m). Blockbuster EpiPen generated lower profits than…

Teva launches Viagra generic in US

Viagra was approved by FDA in 1998 and has fetched Pfizer billions of dollars worldwide since then. Considering the 2003-2014 period, Viagra’s total revenue is $21.975bn, that is $1.83bn per year on average. Viagra is sold at $65 in the…

Amazon negotiates with generics giants Mylan and Sandoz

Rumors on Amazon’s possible debut in the pharma industry are increasing. CNBC has reported that Amazon is negotiating with generics giants Mylan and Sandoz. Mylan’s shares have risen over 3% as the news have started circulating. (Source: CNBC)

Sanofi defends patents on Lantus in the US

Sanofi has filed a patent infringement suit against Mylan in the US District Court for the District of New Jersey. The suit is related to 18 patents. The France-based company seeks to defend its blockbuster Lantus (insulin glargine), also in…

Cerberus and Advent funds join group of companies targeting Teva’s Oncology

Investment funds Cerberus Capital Management and Advent International are reportedly in independent talks to acquire Teva’s European Oncology and Pain Treatment division, allegedly worth $700m-$1bn. The same business unit reportedly drew interest from Mylan and Novartis too. Final offers by…

Hard times and complex dynamics for the generics market

When Teva, the largest generic drugs manufacturer in the world, last Thursday announced poor second-quarter results and a consequent slash of dividends (-75%) and staff (7,000), investors were not extremely surprised, as other generics producers already reported similar trends. Teva,…

Positive opinion by ODAC (FDA) for two biosimilars by Amgen and Mylan

Amgen and Mylan hit a major target as they benefited from FDA’s Oncologic Drugs Advisory Committee (ODAC) positive opinion on the commercialization of two biosimilars – respectively manufactured by each company – to Roche’s cancer drugs Avastin and Herceptin. These…

Mylan’s shareholders oppose $98m bonus to chairman Coury

Mylan’s shareholders voted against paying the group’s executives the 2016 bonus at their annual meeting in Amsterdam today. The decision is due to Mylan’s poor performance – indeed, its shares lost more than 30%, as the US government strongly pressured…

Roche, Mylan announce agreement on biosimilar to Herceptin

Roche, its subsidiary Genentech and Mylan today announced an agreement settling the legal battle between the groups for biosimilar to Roche-Genentech’s Herceptin, co-developed by Mylan and India-based Biocon. As part of the agreement, Mylan will obtain a global commercialization license…

Mylan reports 2016 results and shares immediately rise 4%

US-based pharmaceutical multinational Mylan, with tax domicile in the Netherlands, reported its 2016 financial results, which were beyond expectations, and shares (NASDAQ) immediately rose by over 7%. EpiPen, for anaphylactic shock, is confirmed as Mylan’s blockbuster, yet the generics portfolio…

Stada targeted by Mylan and Novartis

Germany-based pharmaceutical group Stada Arzneimittel is reportedly targeted by Novartis and Mylan. The rumors, which started circulating in London, mention a defense strategy against takeover bids developed by Goldman Sachs bank, which was hired by the pharmaceutical group’s board. Stada…

Mylan announces 3,500 staff cuts

Mylan’s shares (NASDAQ) decreased by as much as 5% after the U.S. Company—headquartered in the Netherlands—announced a severe restructuring which will lead to cut 10% of its global workforce. The measure is aimed at making the company more efficient, following…

Mylan Q3 results affected by $465m settlement for EpiPen

US-based Mylan—incorporated in the Netherlands—announced its financial results for Q3 2016. These did not meet predictions, primarily due to the $465m paid on October 6th to US Authorities for the price policy adopted towards Medicaid for Epipen, Mylan’s life-saving treatment…

Abbott: positive quarter, but still no decision on Mylan’s share sale

It is not commonly known that Mylan’s main shareholder is Abbott Laboratories, holding 13% of shares, which yesterday announced its third-quarter results. Abbott took the opportunity to inform shareholders it has written down its investment ($947m) in Mylan following the…

Lupin and Mylan as well interested in Bayer’s dermatology business

Bloomberg reported today that even India-based Lupin and US-based Mylan are among the groups interested in Bayer’s dermatology business. The two groups join the companies reported to have already expressed interest in the business – Torrent Pharmaceuticals, Cadila Healthcare and…